Loading organizations...
Key people at Shinsei Capital Partners.
Shinsei Capital Partners was founded in 2019 by Manabu Nakamura (Founder, CEO and Managing Partner).
Shinsei Capital Partners is a Tokyo-based venture capital firm dedicated to life sciences, funding biotech companies across all stages, from early seed to later rounds. The firm provides capital and strategic guidance, leveraging its team's deep expertise in finance and pharmaceutical development. It cultivates innovative technologies addressing critical medical needs and translating research into applications.
Managing Partner Manabu Nakamura established the firm on February 7, 2019. Nakamura's extensive venture capital background includes serving as Managing Director of Shinsei Corporate Investment since 2012. His insight recognized the untapped potential in Japanese life science research, underscoring the need for specialized capital and support to commercialize these advancements.
The firm primarily invests in early to late-stage biotech startups. Shinsei Capital Partners' mission is to accelerate innovative medicines and technologies for global patients, contributing to healthcare's future. It fosters a dynamic ecosystem where scientific discoveries rapidly evolve into impactful medical solutions.
Key people at Shinsei Capital Partners.
Shinsei Capital Partners was founded in 2019 by Manabu Nakamura (Founder, CEO and Managing Partner).
Shinsei Capital Partners has 1 tracked investment across 1 company. The latest tracked deal is $44.6M Series D in Promethera Biosciences in May 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 7, 2019 | Promethera Biosciences | $44.6M Series D | Shinsei Capital Partners | Cyril Janssen, Marc Speeckaert, Olivier VAN DER Rest, Ci:z Investment, Korea Investment Partners, MEDIPAL HOLDINGS CORPORATION, Mirae Asset Capital, Mitsui & CO. Global Investment, SIX Snow |
